RBD-5044 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hyperlipidemia. According to GlobalData, Phase I drugs for Hyperlipidemia have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RBD-5044’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RBD-5044 overview

SR-044 is under development for the treatment of hyperlipidemia. The therapeutic candidate is a small interference RNA (siRNA). It acts by targeting apolipoprotein C III (APOC3) and is based on RNA interference (RNAi) technology called RIBO-GalStar. It is administered through subcutaneous route.

Suzhou Ribo Life Sciences overview

Suzhou Ribo Life Sciences (Ribo) is a drug development company that develops nucleic acid drugs and related products based on the RNA interference (RNAi) technology. The company’s pipeline products include QPI-1007, RB-RQ007, RB-T2D003, RB-PCA006, RB-AG010 and others. Ribo also develops RBP131, a lipid nanoparticle based and liver-targeted delivery system for systemic delivery siRNA drug. The company’s RNAi platform develops biomedicine and is capable of “silencing” genes specifically using RNAi. Ribo is headquartered in Kunshan, Jiangsu, China.

For a complete picture of RBD-5044’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.